Stress Disorder, Post Traumatic Clinical Trial
Official title:
Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)
The purpose of this study is to investigate a new use for a medication called levodopa (L-DOPA). L-DOPA has been approved for use in Parkinson 's disease, but not for Posttraumatic Stress Disorder (PTSD). L-DOPA is thought to enhance certain cognitive abilities that the investigators believe may be affected among women with PTSD. It is hypothesized that L-DOPA may enhance fear extinction learning to a conditioned fear stimulus. If this is true, L-DOPA may improve outcomes for those undergoing certain types of therapy for PTSD, though that aim is beyond the scope of this project. Additionally, the investigators are testing whether an individual's genetic profile affects how well L-DOPA works to enhance cognitive abilities.
Current state-of-the art treatments for posttraumatic stress disorder (PTSD) are lacking in
efficacy. There are two main evidence-based psychological treatments for PTSD. Prolonged
Exposure (PE) is a largely-exposure based intervention that has been found efficacious for
the reduction of PTSD symptoms; however, PE is associated with post-treatment remission rates
of only ~53-60%. Cognitive Processing Therapy (CPT) is also a widely studied and efficacious
psychological treatment for PTSD, which focuses both on exposure to the trauma memory as well
as cognitive therapy techniques. As with PE, post-treatment remission rates for CPT are only
~53-60%, thus also indicating need for improvement in overall efficacy and consistency of
response across individuals.
There is emerging research demonstrating that dopamine is critical to the consolidation and
subsequent recall of fear extinction learning. A recent study of healthy adult humans
demonstrated that oral administration of 150 mg L-DOPA after fear extinction learning led to
decreased fear responding, even when tested in a new context. Further, this study also found
that resting-state functional connectivity, measured ~45 minutes after post-extinction
learning L-DOPA administration, between the ventral tegmental area (VTA) and mPFC was
correlated with magnitude of medial prefrontal cortex (mPFC) recruitment during recall of the
fear extinction learning. This latter finding suggests that the mechanism by which L-DOPA
boosts consolidation of fear extinction learning is through acutely reorganized dopaminergic
resting-state networks. Indeed, other studies have demonstrated an acute effect of L-DOPA
administration on resting-state functional connectivity within dopaminergic neural networks.
Thus, agents that increase dopamine transmission acutely during the post-extinction learning
consolidation window, and thereby acutely altering organization of dopaminergic neural
networks, show promise for boosting the consolidation of fear extinction memories and
decreasing fear responding.
Genetic variation is a primary contributor to individual differences in baseline dopamine
neurotransmission. Individuals with specific alleles in genes coding for high baseline
dopamine demonstrate better performance on tasks probing working memory, cognitive control,
and social cognition. Genetic variants in baseline dopamine neurotransmission would therefore
be expected to modulate performance-enhancing effects of L-DOPA, such that individuals with
low endogenous would be expected to have increased performance upon exogenously increasing
dopamine neurotransmission; whereas individuals with high endogenous dopamine would be
expected to have performance deteriorate from exogenously increasing dopamine
neurotransmission. In support of this hypothesis, a recent study found an interaction between
L-DOPA administration and endogenous dopamine neurotransmission (as indicated by a polygenic
score pooled across catechol-O-methyltransferase (COMT), dopamine transporter protein (DAT),
dopamine D1 receptor (DRD1-3)) on motor learning performance, such that individuals with a
combination of alleles coding for higher baseline dopamine demonstrated a weaker learning
benefit from L-DOPA, whereas individuals with a combination of alleles coding for lower
baseline dopamine demonstrated a stronger learning benefit from L-DOPA. These data
demonstrate the non-linear relationship between performance and dopamine levels, suggesting
that any investigation of potential effects of boosting dopamine neurotransmission as a means
of boosting learning needs to account for baseline dopamine neurotransmission.
Overall, the proposed project seeks to demonstrate the engagement of post-extinction dopamine
neurotransmission and downstream acute reorganization of dopaminergic resting-state neural
networks as a means of increasing consolidation of generic fear extinction learning in adult
women with PTSD.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00356278 -
D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD
|
Phase 2/Phase 3 | |
Completed |
NCT00635635 -
Guided Imagery for Military Sexual Trauma-Related Posttraumatic Stress Disorder (PTSD)
|
N/A | |
Terminated |
NCT03990064 -
Benefits of Relaxation by Music Therapy on PTSD Symptoms
|
N/A |